Annual Report

Overview

The report describes Pharming's strong 2019 growth, with annual revenues rising to €169 million and net profit reaching €36.2 million. It also highlights expansion of the RUCONEST® pipeline through pre-eclampsia, acute kidney injury, Pompe disease, Fabry disease, and the licensed leniolisib program. Corporate Social Responsibility disclosures emphasize animal welfare, patient safety, ethical conduct, climate impact, supply-chain traceability, and employee wellbeing. Year-end headcount increased to 212 employees.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2019
Period: Ends 31 December 2019
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services